Jobs
View more job listings or post a job
Applied Cells Research Associate
Applied Cells Application Scientist
Juvena Therapeutics Principal Data Scientist – Drug Discovery & Development
Juvena Therapeutics Senior Computational Biologist – Proteomics
Peak Bio Research Associate - Translation
Peak Bio Director, Antibody Drug Conjugate CMC
Peak Bio Cell/Tumor Biologist - Scientist
Peak Bio Research Associate - Molecular and Cell Biology
Peak Bio Senior Research Associate/Scientist - Protein Production
Peak Bio Analytical/Bioanalytical Scientist
Post a job

Workshop

Webcast: Conducting Clinical Trials in China – Regulatory and Clinical Challenges and Recent Developments for Drug and Device Development; Lessons for US-based Companies Entering the China Market


Speakers: Lan Huang (BeyondSpring); John Mao (Foresee Pharma); Vivian Mao (Abbott Vascular); Honggang Bi (Covance China); Guobin Wang (PPD China)
Organizers:
Date: 2017-09-21
Time: 14:00-16:30 Pacific Time
Registration fee: (USD):
Location: Online Webcast ONLY
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2017-09-21  (it will close sooner if the seating cap is reached)

About the Topic

Pharmaceutical and Medical Device companies today face a growing demand to expand their clinical trial programs into China in order to access the vast pool of patients. While there are clear benefits for conducting clinical trials in China, there are significant operational and regulatory challenges, which need to be addressed before overseas companies plan to conduct trials in China, either as a trial conducted solely in China or as part of a multinational trial involving Chinese patients. It is important that appropriate measures are put in place to satisfy the ever evolving Chinese clinical trial and approvability standards. In the meantime, the China FDA (CFA) has initiated a major effort to harmonize the regulatory and clinical practices with the developed world and has implemented a number of policies that have profound impact on the clinical and regulatory practices in China.

This workshop aims at discussing some of the regulatory and operational challenges when conducting clinical trials in China, in both, the Pharma and Medical device arena. The presenters who are industry leaders with deep experience with drug and device development in China will review some of the recent regulations for the Pharma and Device development in China and suggest ways to approach China’s FDA (CFDA). It will discuss challenges and solutions when conducting national or multinational device trials in China from the perspectives of a local Chinese CRO as well as global CROs with affiliates in China. The workshop will provide examples for early strategies to include China in the development as part of a global development plan. A case example will demonstrate how a global clinical Phase 3 trial would suffice for a US FDA and China FDA approval.


About the Speakers

Lan Huang, PhD, BeyondSpring (Co-founder & CEO) 
John Mao, PhD, Foresee Pharma (SVP) 
Vivian Mao, MD, Abbott Vascular (Associate Director, Clinical Science) 
Honggang Bi, PhD, Covance China (Corporate Vice President and General Manager) 
Guobin Wang, PhD, PPD China (Director, Project Management)


2022-10-21, [Free Online Workshop] MicroPhysiological Systems (MPS) such as "Organ-on-a-Chip" as a Tool For Drug Candidate Evaluation: Technologies, Applications and Regulatory Aspects
2022-11-02, [Free Online workshop] Bispecific Antibodies: Discovery, Engineering, Development and Regulatory Considerations
2022-11-14, [Free Online Symposium] Preclinical and Clinical Development of Cell-based Cancer Immunotherapies: Discovery, Translational PKPD, Safety, Biomarkers, Immunogenicity, CMC, Clinical Pharmacology & Clinical Trials (co-organized by AAPS)
2022-12-06, [Free Online Symposium] Gene Therapy: Discovery, Development and Regulatory Perspectives
©Pharmaceutical & BioScience Society, International; Last Modified: 9/26/2022; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

iPRECIO Programmable Pumps PK/PD models and the limitations of traditional dosing methods. Methods & benefits of implantable microinfusion pumps in both rats & mice.
iPRECIO Programmable Pumps Evaluate drug efficacy in animal models in a clinically relevant manner with a Programmable Refillable and implantable pump. 3Rs and group housed.
Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad